

Supplemental Data

Risk and outcome of secondary primary malignancies after radioactive iodine treatment in differentiated thyroid cancer patients

Xiaoran Mei, Xiaoqin Yao, Fang Feng, Weiwei Cheng, Hui Wang




Figure S1. The spectrum of SPMs in patients treated with and without RAI.

	Incidence in all DTC survivors	Number of patients, n(%)	
		+RAI	-RAI
All cancer combined	4.4%	2289	2339
Oral Cavity and Pharynx	0.1%	56(2.4%)	51(2.2%)
Digestive System	0.6%	319(13.9%)	356(15.2%)
Respiratory System	0.5%	247(10.8%)	254(10.9%)
Skin	0.3%	138(6.0%)	137(5.9%)
Breast	1.1%	547(23.9%)	574(24.5%)
Female Genital System	0.4%	179(7.8%)	206(8.8%)
Male Genital System	0.5%	237(10.4%)	233(10.0%)
Urinary System	0.4%	194(8.5%)	191(8.2%)
Nervous System	0.1%	30(1.3%)	36(1.5%)
Hematologic System	0.5%	261(11.4%)	215(9.2%)

Table S1. The incidence of SPMs in all DTC survivors and the proportion of each system of SPMs by their site.

	Crude RR (95% CI)	P value
All cancer combined	1.01(0.95-1.07)	0.749
Oral Cavity and Pharynx	1.13(0.78-1.66)	0.520
Digestive System	0.92(0.79-1.08)	0.310
Respiratory System	1.00(0.84-1.20)	0.971
Skin	1.04(0.82-1.31)	0.750
Breast	0.98(0.87-1.11)	0.778
Female Genital System	0.90(0.73-1.10)	0.286
Male Genital System	1.05(0.88-1.26)	0.602
Urinary System	1.05(0.86-1.28)	0.647
Nervous System	0.86(0.53-1.40)	0.541
Hematologic System	1.25(1.05-1.50)	0.015

Table S2. The crude relative risk of SPMs associated with RAI treatment by the site of SPMs.